Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy

Anti-programmed death 1 (PD-1) immune checkpoint inhibitors enhance the antitumour activity of the immune system and have produced durable tumour responses in several solid tumours including non-small cell lung cancer (NSCLC). However, PD-1 inhibitors can lead to immune-related adverse events, inclu...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMJ Case Rep
Main Authors: Andruska, Neal, Mahapatra, Lily, Hebbard, Carleigh, Patel, Priyank, Paul, Vishesh
פורמט: Artigo
שפה:Inglês
יצא לאור: BMJ Publishing Group 2018
נושאים:
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6194409/
https://ncbi.nlm.nih.gov/pubmed/30301729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2018-225937
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים